
ALXO Stock Forecast & Price Target
ALXO Analyst Ratings
Bulls say
ALX Oncology Holdings Inc. is poised for significant revenue growth, with projections indicating an increase from $45 million in 2032 to $278 million by 2034, showcasing a strong upward trajectory in its financial outlook. The company's strategic decisions have successfully extended its cash runway into the fourth quarter of 2026, allowing for focused investment in its clinically de-risked breast and colorectal cancer programs utilizing the CD47 blocker, evorpacept. This combination of projected revenue growth and extended cash runway highlights the company's potential for sustained development and innovation in the immuno-oncology space.
Bears say
ALX Oncology Holdings Inc reported a net loss of $0.58 per share for 1Q25, which exceeded the consensus estimate of a $0.47 loss per share, reaffirming concerns about the company's financial health amidst a lack of revenue. Furthermore, the decision to discontinue evaluations of its candidate Evo for head and neck squamous cell carcinoma and bladder cancer, due to subpar clinical data, highlights potential challenges in advancing its product pipeline. The FDA's request for a Phase 3 study, citing insufficient data from the Phase 2 ASPEN-06 study for accelerated approval, further compounds the company's negative outlook by indicating potential delays and additional costs in achieving regulatory milestones.
This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ALXO Analyst Forecast & Price Prediction
Start investing in ALXO
Order type
Buy in
Order amount
Est. shares
0 shares